Focuses on developing small molecules to restore neuronal health and stop neurodegeneration in diseases such as Alzheimer's.
Athira Pharma, Inc., a prominent late clinical-stage biopharmaceutical firm based in Bothell, Washington, specializes in pioneering small molecule therapies aimed at restoring neuronal health and mitigating neurodegeneration. At the forefront of its pipeline is ATH-1017, a breakthrough blood-brain barrier-penetrating HGF/MET positive modulator currently advancing through Phase 3 trials under the LIFT-AD program and Phase 2 trials under ACT-AD, targeting Alzheimer's disease. Additionally, the company is investigating ATH-1017 in Phase 2 trials for Parkinson's disease. Beyond ATH-1017, Athira Pharma is actively developing other promising product candidates such as ATH-1019, focusing on peripheral nervous system disorders, and ATH-1020, designed for neuropsychiatric conditions.
Originally founded as M3 Biotechnology, Inc. in 2011, Athira Pharma underwent a significant rebranding in April 2019 to reflect its expanding scope and strategic focus. The company's commitment to innovation in neuroscience underscores its mission to address critical unmet medical needs through rigorous clinical research and development. With a dedicated team of researchers and professionals, Athira Pharma continues to leverage its deep understanding of neurological mechanisms to advance novel treatments that hold promise for patients suffering from debilitating neurodegenerative diseases.
Headquartered in Bothell, Washington, Athira Pharma operates at the nexus of biopharmaceutical innovation, drawing upon cutting-edge scientific insights and strategic partnerships to drive its clinical programs forward. The company's pioneering approach and commitment to scientific excellence position it as a key player in the quest to redefine treatment paradigms in neurology, offering hope to millions affected by the challenges of neurodegenerative disorders worldwide.